Survival according to CEBPA and WT1 mutation status. (A) EFS for patients with CEBPA mutations and for patients with wt CEBPA. (B) EFS for patients with WT1 mutations compared with wt WT1 patients. (C) EFS stratified according to FLT3-ITD and WT1 mutation status.